



GIAN LIFE CARE LIMITED

Regd Office:- 7/216 (6), Swaroop Nagar (Infront of
L.L.R. Hospital), Kanpur, Uttar Pradesh - 208002
CIN: L85100UP2018PLC110119; Mobile: 8808051576
Website: <http://gianpathlab.com/>;
Email: gpxreport@gmail.com

March 02, 2022

To,
Asst. General Manager
Dept of Corp. Services,
BSE Limited,
P. J. Towers, Dalal Street, Fort,
Mumbai: 400 001.

Scrip Code:- 542918

Sub: Outcome of Board Meeting held on Wednesday, the 2nd day of March, 2022

Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today i.e 2nd day of March, 2022, has *inter-alia* considered and approved the following:-

1. Standalone Financial Statements for the Quarter ended 31st December, 2021. (Signed Copy along with Limited Review Report is enclosed).

The Board Meeting commenced at 12:00 Noon and concluded at 01:00 P.M.

You are requested to kindly take the above information in your records.

Thanking You,

Yours faithfully,

For GIAN LIFE CARE LIMITED

(Arun Kumar Gupta)
Managing Director
DIN:- 01331593
Encl:- As above



Independent Auditor's Review Report on quarterly and nine monthly unaudited Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Gian Life Care Limited

1. We have reviewed the accompanying statement of unaudited financial results of Gian Life Care Limited ("the Company") for the quarter ended December 31, 2021 and year to date from April 01, 2021 to December 31, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHARPAARTH & CO.
Chartered Accountants
ICAI Firm Registration No. 132748W

Harshal Jethaje (Partner)
Membership No. 141162
Jalgaon
02nd March, 2022
UDIN : 22141162ADXOMX1558



SHARP AARTH & CO

Mumbai | Nashik | Pune | Jalgaon | Ichalkaranji | Ahmedabad | Jaipur | Udaipur | Kota

2nd Floor, Deep Plaza, Opp New B J Market, Above Akash Plywood, Jalgaon, Maharashtra - 425001

☎ 0257-2232262 ☎ +91-9422211962 ✉ jalgaon@sharparth.com
☎ +91-9028511962 🌐 www.sharparth.com



GIAN LIFE CARE LIMITED

Regd Office:- 7/216 (6), Swaroop Nagar (Infront of L.L.R. Hospital), Kanpur, Uttar Pradesh - 208002
 CIN: L85100UP2018PLC110119; Mobile: 8808051576
 Website: <http://gianpathlab.com/>;
 Email: gpxreport@gmail.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER / NINE MONTHS ENDED DECEMBER 31, 2021

Amount Rs. in Lacs

Sr. No.	Particulars	Quarter Ended	Six months Ended	Nine months Ended	For the Year Ended
		31.12.2021	30.09.2021	31.12.2021	31.03.2021
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	611.57	734.77	1,346.35	1,045.50
II	Other Income	6.81	15.15	21.95	29.01
III	Total Revenue(I+II)	618.38	749.92	1,368.30	1,074.50
IV	Expenses				
	(a) Cost of materials consumed	68.58	159.68	228.27	357.11
	(b) Employee benefits expense	39.11	46.53	85.64	94.23
	(c) Finance Cost	4.53	9.91	14.44	30.17
	(d) Depreciation and amortisation expense	8.36	15.50	23.86	28.53
	(e) Other Expenses	107.53	168.06	275.59	288.99
	Total Expenses	228.11	399.68	627.79	799.03
V	Profit before exceptional and extraordinary items and tax (III - IV)	390.27	350.25	740.52	275.48
VI	Exceptional Items	-	-	-	-
VII	Profit before extraordinary items and tax (V - VI)	390.27	350.25	740.52	275.48
VIII	Extraordinary Items	-	-	-	-
IX	Profit before tax (VIII - VIII)	390.27	350.25	740.52	275.48
X	Tax Expenses :				
	(1) Current Tax	97.94	88.37	186.31	73.17
	(2) MAT Expenses	-	-	-	1.93
	(3) Tax of Previous Year	-	-	-	2.28
	(4) Deferred Tax	0.29	0.08	0.21	0.24
XI	Profit / (Loss) from Period from continuing operations (VII - VIII)	292.04	261.96	554.00	201.72
XII	Profit (Loss) from discontinuing Operations	-	-	-	-
XIII	Tax Expense of Discontinuing operations	-	-	-	-
XIV	Profit / (Loss) from Discontinuing operations (After Tax XII- XIII)	-	-	-	-
XV	Profit (Loss) for the period (XI +XIV)	292.04	261.96	554.00	201.72
XVI	Earnings Per Share of Rs. 10 Each				
	(a) Basic (Rs.)	6.21	5.57	11.79	4.29
	(b) Diluted (Rs.)	6.21	5.57	11.79	4.29

for Kase




GIAN LIFE CARE LIMITED

Regd Office:- 7/216 (6), Swaroop Nagar (Infront of
L.L.R. Hospital), Kanpur, Uttar Pradesh - 208002
CIN: L85100UP2018PLC110119; Mobile: 8808051576
Website: <http://gianpathlab.com/>;
Email: gpxreport@gmail.com

Notes:-

- The Audit Committee has reviewed, and the Board of Directors has approved the above results and its release at their respective meetings held on 02nd March, 2022. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company runs laboratories for carrying out pathological investigations.
- There were no investor complaints received / pending as at 31st December, 2021
- The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.
- The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company's operations and revenue during the period were impacted due to COVID-19. However, it has no further significant impact with respect to COVID 19 pandemic during the quarter ended December 31, 2021. The Company is authorised by ICMR to perform COVID-19 tests using RT-PCR technology.
- Previous period/year's figures have been regrouped/reclassified wherever required, to make them comparable with the figures for the current period.

For Gian Life Care Limited,


(Dr. Arun Kumar Gupta)
Managing Director
(DIN NO:01331593)



Kanpur
02.03.2022